Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. (NEOPREDICT)

a Multicenter Phase II Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) exhibits significant heterogeneity, making the optimal choice of chemotherapy challenging. While targeted therapies benefit from companion biomarkers, few tools exist to guide the selection of cytotoxic chemotherapy. Transcriptomic signatures now allow for the prediction of sensitivity to cytotoxic agents. Several molecular classifications (such as basal-like, classical, etc.) have been established and correlated with prognosis, but they are rarely used in clinical practice. The PaCaOmics program has developed robust predictive signatures, grouped under the name Pancreas-View Signature, capable of analyzing FFPE samples using minimal material.

Locally advanced or borderline resectable pancreatic cancer (BR-PDAC) accounts for approximately 20% of cases. Neoadjuvant chemotherapy (NAC) has become the standard of care, improving R0 resection rates and overall survival. The two main chemotherapy regimens used are mFOLFIRINOX and GEM/NAB-paclitaxel, which show comparable efficacy and toxicity profiles. However, no clear consensus exists on the superiority of one over the other. Therefore, predictive biomarkers are crucial to help select the most appropriate neoadjuvant regimen, avoid unnecessary toxicities, and maximize the chances of curative surgery. The NEOPREDICT trial aims to evaluate the efficacy of treating patients with borderline resectable PDAC identified with a GEM+ sensitivity transcriptomic signature with GEMCITABINE + NAB-PACLITAXEL regimen compared to standard of care mFOLFIRINOX as NAC.

Study Overview

• Status: Not yet recruiting
• Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma
• Intervention / Treatment: Drug: Nab paclitaxel / gemcitabine; Drug: mFOLFIRINOX

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Falilatou SAKA; Phone Number: 0658636325; Email: prodige104.neopredict@ffcd.fr

Study Locations

• France
  • Clichy, France
    • Hôpital Beaujon
    • Contact: Maher AKEZ; Email: maher.akez-ext@aphp.fr
    • Principal Investigator: Louis De Mestier, MD
  • Marseille, France
    • Institut Paoli Calmettes
    • Contact: Christophe BOUVIER; Email: BOUVIERC3@ipc.unicancer.fr
    • Principal Investigator: Brice CHANEZ, MD
  • Pierre-Bénite, France
    • Hôpital Lyon Sud
    • Contact: Maëlys SIEGWALD; Email: maelys.siegwald@chu-lyon.fr
    • Principal Investigator: Marion CHAUVENET, MD
  • Saint-Priest-en-Jarez, France
    • Hopital Nord Chu Saint Etienne
    • Principal Investigator: Nicolas WILLIET, MD
    • Contact: Fabrice DI PALMA, PhD; Email: fabrice.dipalma@chu-st-etienne.fr
  • Toulouse, France
    • Hôpital Rangueil
    • Principal Investigator: Nadim FARES, MD
    • Contact: Caroline GREGOIRE; Email: gregoire.c@chu-toulouse.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) defined by National Comprehensive Cancer Network (NCCN) criteria v2.2025 on contrast-enhanced CT-scan (including non-contrast acquisition, pancreatic phase and portal venous phase), with stage confirmed by a local pancreatic expert review board including at least medical oncologist/onco-gastroenterologist, pancreatic surgeon and pancreatic expert radiologist. No central review is required,
• Measurable pancreatic lesion according to RECIST 1.1 (CT scan or MRI < 28 days),
• WHO PS 1 or 0,
• Histologically proven pancreas ductal adenocarcinoma,
• Available FFPE from pancreatic tumor sample with > 10% of tumor cells (assessed by a local expert pancreatic pathologist),
• No prior chemotherapy or radiation for pancreatic cancer (except one cycle of mFOLFIRINOX during waiting time for GEM + signature) or resection of pancreatic cancer,
• Age ≥18 years old and ≤ 80 years old if geriatric standardized evaluation validates the study chemotherapy regimen administration for patients between 75-80,
• Written informed consent obtained from patient before any protocol related intervention,
• Acceptation and ability to conform to the protocol requirement during all the duration of the investigation including treatment, scheduled visits, clinical and biological examinations and follow up,
• Adequate organ function, as defined by the following:
• AST and ALT < 3.5 x upper limit of normal (ULN),
• Total serum bilirubin < 3 x ULN, (for patients with total serum bilirubin between 1.5 and 3 x ULN, the dose of irinotecan will be adjusted in accordance with the SmPC).
• Serum albumin >30 g/L,
• Hemoglobin >9.0 g/dl,
• Absolute neutrophil count (ANC) >1.5 G/L,
• Platelets >100 G/L,
• Creatinine clearance > 50 mL/min (according to CKD-EPI),
• Normal Kalemia, calcemia, magnesemia
• Women of childbearing potential must agree to use contraception during treatment and for at least 15 months after discontinuation of the experimental treatments. Men who have sexual relationship with women of childbearing potential must agree to use contraception during treatment and for at least 12 months after discontinuation of the experimental treatments.
• Patient affiliated to French social security

Exclusion Criteria:

• Strictly resectable or locally advanced PDAC according to NCCN criteria,
• Distant metastases (including inter aortic lymph nodes),
• Any condition that contraindicates the use of IRINOTECAN, OXALIPLATIN, 5FU, GEMCITABINE or NAB-PACLITAXEL,
• Partial or complete DPD deficiency (uracilemia ≥ 16 ng/mL),
• Any progressive pathology not stabilized over the past 6 months: liver impairment, renal impairment, respiratory or cardiac failure.
• Other concomitant cancer or a history of cancer during the previous 3 years, except for localized cancer in situ, basal or squamous cell skin cancer adequately treated,
• Other interventional clinical trial except for non-interventional trial (ie not modifying 1-year EFS),
• QT/QTc (Fredericia Correction) interval > 450 msec for men and > 460 msec for women,
• Pregnant or breastfeeding woman,
• Known Gilbert's syndrome or known homozygosity for UGAT1A1*28 polymorphism,
• Treatment with millepertuis,
• Uncompensated asthma,
• Potentially severe infection < 7 days,
• Inflammatory bowel disease and/or intestinal obstruction,
• Known severe allergy to contrast dye (for CT or MRI) without possible substitution,
• Hypersensitivity to the active substance or to one of the excipients of one of the study treatments,
• Treatment with brivudine within 4 weeks prior to the administration of protocol treatment,
• Concomitant treatment with a strong inhibitor (i.e. ketoconazole) or inducer (i.e. rifampicin, carbamazepine, phenobarbital, phenytoin, apalutamide) of cytochrome P450 3A4 or 2C8 (CYP3A4 or CYP2C8),
• Patient who has received a live attenuated vaccine (against yellow fever, chickenpox, shingles, measles, mumps, rubella, tuberculosis, rotavirus) in the 6 weeks prior to randomization,
• Patient with sensitive peripheral neuropathy with functional discomfort,
• Impossibility of undergoing medical monitoring during the trial for geographical, social, or psychological reasons,
• Patient who is under judicial protection (patient who is legally institutionalized or under guardianship or curatorship) or not able to give consent. (as refered at art. art. L. 1121-6, art. L. 1121-8, art. L. 1121-8-1 du Code de la Santé Publique)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NAB-PACLITAXEL - GEMCITABINE Arm; NAB-PACLITAXEL 125 mg/m2 on day 1, 8 and 15 + GEMCITABINE 1000 mg/m2 on day 1, 8 and 15.	Drug: Nab paclitaxel / gemcitabine; NAB-PACLITAXEL 125 mg/m2 (30 min infusion) on day 1, 8 and 15. GEMCITABINE 1000 mg/m2 over 30 min infusion on day 1, 8 and 15.
Active Comparator: mFOLFIRINOX Arm; Oxaliplatin 85 mg/m2 + Folinic acid 400 mg/m2 (or Leucovorin 200 mg/m²) + Irinotecan 180 mg/m2 (150 mg/m2 for older patient after SGA) + 5-FU 2400 mg/m2 as a continuous IV infusion over 46 hours	Drug: mFOLFIRINOX; Oxaliplatin 85 mg/m2 as a 2-hour IV infusion on day 1. Folinic acid 400 mg/m2 (or Leucovorin 200 mg/m²) as a 2-hour IV infusion (after end of oxaliplatin), in Y with irinotecan on day 1. Irinotecan 180 mg/m2 (150 mg/m2 for older patient after SGA) for 1h30 on day 1 (30 min after beginning of folinic acid). 5-FU 2400 mg/m2 as a continuous IV infusion over 46 hours, from day 1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event Free Survival	Event Free Survival (EFS) will be calculated from the date of randomization to the date at which the first event occurs. Patients alive without any event will be censored at the date of last news.Events to be considered for the endpoint will be: Disease progression, No pancreatic resection (all causes), Death whatever the cause, Grade IV febrile neutropenia or grade IV diarrhea during NAC.	at 1 year after randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objectif Response Rate (ORR)	Objective Response rate (ORR) will be evaluated with RECIST 1.1 criteria by the investigator regarding the scans during the NAC. The objective response rate is defined as % of patients with a complete or a partial response.	At 16 weeks after randomization

Collaborators and Investigators

• Sponsor: Federation Francophone de Cancerologie Digestive

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): April 1, 2029
• Study Completion (Estimated): April 1, 2031

Study Registration Dates

• First Submitted: May 11, 2026
• First Submitted That Met QC Criteria: May 29, 2026
• First Posted (Actual): June 1, 2026

Study Record Updates

• Last Update Posted (Actual): June 1, 2026
• Last Update Submitted That Met QC Criteria: May 29, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Health Care Economics and Organizations; Economics; Gemcitabine; Taxes
• Other Study ID Numbers: PRODIGE 104 A (FFCD 2307); 2024-519753-11-00 (Ctis)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No